Status:

COMPLETED

Sexual Functioning Study With Antidepressants

Lead Sponsor:

GlaxoSmithKline

Conditions:

Depressive Disorder, Major

Major Depressive Disorder (MDD)

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Effects of two depression medication on sexual functioning

Detailed Description

A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Ex...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Primary diagnosis of Major Depressive Disorder (MDD)
  • must have met DSM-IV criteria for current major depressive episode for at least 8 weeks but no long than 2 years.
  • HAM-D17 total score of \>17 at screening and baseline.
  • Severity of illness score of \>4 at screening and baseline.
  • Willing to discuss sexual functioning with investigator or designee.
  • Sexual activity that leads to orgasm at least every 2 weeks.
  • Exclusion Criteria:
  • Past or current DSM-IV diagnosis of Bipolar Disorder I or II, schizophrenia or another psychotic disorder(s).
  • Primary DSM-IV diagnosis or received treatment for Panic Disorder, Obsessive Compulsive Disorder or Post Stress Disorder within previous 12 months.
  • Poses a homicidal or serious suicidal risk, have made an attempt within months prior to screening or who has ever been homicidal.
  • Myocardial infarction with 1 year of screening.
  • Taken ibupropion hydrochloride or venlafaxine in the last 6 months.
  • Positive urine test for illicit drug use or alcohol or substance abuse within the past 12 months.
  • Psychotherapy within 3 months.
  • Pregnant.
  • Electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior of screening.
  • ECG or clinical evidence of atrial or ventricular hypertrophy.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2004

    Trial Type :

    INTERVENTIONAL

    End Date :

    May 1 2005

    Estimated Enrollment :

    347 Patients enrolled

    Trial Details

    Trial ID

    NCT00316160

    Start Date

    September 1 2004

    End Date

    May 1 2005

    Last Update

    May 30 2017

    Active Locations (45)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 12 (45 locations)

    1

    GSK Investigational Site

    Mesa, Arizona, United States, 85210

    2

    GSK Investigational Site

    Phoenix, Arizona, United States, 85023

    3

    GSK Investigational Site

    Scottsdale, Arizona, United States, 85251

    4

    GSK Investigational Site

    Little Rock, Arkansas, United States, 72223